Coherus Oncology (CHRS) Net Income Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Net Income Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 32.96%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.59%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 19.97%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -46.86%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Coherus Oncology 199.14 Mn 32.09 Mn 8.50 Mn 73.61%

Historic Data

Download Data
DateValue
Mar 31, 2026 73.61%
Dec 31, 2025 29.02%
Sep 30, 2025 28.13%
Jun 30, 2025 106.71%
Mar 31, 2025 54.30%
Dec 31, 2024 -26.39%
Sep 30, 2024 43.52%
Jun 30, 2024 50.40%
Mar 31, 2024 44.04%
Dec 31, 2023 -132.23%
Sep 30, 2023 -50.66%
Jun 30, 2023 -39.70%
Mar 31, 2023 -60.40%
Dec 31, 2022 -51.82%
Sep 30, 2022 -56.62%
Jun 30, 2022 -60.42%
Mar 31, 2022 -68.72%
Dec 31, 2021 80.24%
Sep 30, 2021 13.16%
Jun 30, 2021 11.87%